GPR183 and systemic lupus erythematosus: As EBI2 and/or its oxysterol ligands are upregulated in B cell malignancies and autoimmune diseases (Type 1 Diabetes, rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis), two EBI2 modulators are being developed.